Randomized phase III trial comparing in a preoperative schedule the result of two concurrent chemoradiation schemes (45 Gy + capecitabine vs 50 Gy + capecitabine - oxaliplatin) on the rate of sterilization of the operative specimen in resectable rectal carcinomas T3-4 N0-2 M0.

Trial Profile

Randomized phase III trial comparing in a preoperative schedule the result of two concurrent chemoradiation schemes (45 Gy + capecitabine vs 50 Gy + capecitabine - oxaliplatin) on the rate of sterilization of the operative specimen in resectable rectal carcinomas T3-4 N0-2 M0.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRODIGE-2
  • Most Recent Events

    • 12 Sep 2017 Results assessing the impact of Immune response-associated gene polymorphisms on tumor response (n=316) presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jun 2017 Results assessing the impact of gene polymorphisms on tumour response (n=316), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top